Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Biogen Idec to acquire full rights and control of Tysabri from Elan for upfront cash and contingent payments
Change and processes of change within interventions to promote adjustment to multiple sclerosis: Learning from patient experiences.
Patients' experiences of adapting to multiple sclerosis: a qualitative study.
Gray matter involvement in multiple sclerosis.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Perceived impact of spasticity is associated with spatial and temporal parameters of gait in multiple sclerosis.
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
[Levels of Beclin 1 and LC3 in peripheral blood mononuclear cells of patients with multiple sclerosis and neuromyelitis optica and its significance].
Impact of Clear, Loud and Slow Speech on Scaled Intelligibility and Speech Severity in Parkinson's Disease and Multiple Sclerosis.
Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors.
[Neuromyelitis optica spectrum disorder: a case report].
[HTLV-1-associated myelopathy/tropical spastic paraparesis : A differential diagnosis in multiple sclerosis.]
CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.
Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis.
The Implication of Vitamin D and Autoimmunity: a Comprehensive Review.
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis.
Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis.
Role of Platelets in Neurodegenerative Diseases: A Universal Pathophysiology.
Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.
The gut microbiome in multiple sclerosis.
Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review.
MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
The role of microglial activation in disease progression.

Pages